Product Description
Collagenase clostridium histolyticum injection is used to treat Dupuytren's contracture with a palpable cord. It is also used to treat Peyronie's disease with a palpable plaque and curvature deformity in men. (Sourced from: https://www.mayoclinic.org/drugs-supplements/collagenase-clostridium-histolyticum-injection-route/description/drg-20073911)
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Oral, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Bulgaria | Canada | European Medicines Agency | Greece | Hungary | Ireland | Lithuania | Malaysia | Poland | Portugal | Slovakia | Slovenia | Sweden
Approved Indications: None
Known Adverse Events: None
Company: Endo
Company Location: DUBLIN 4 L2 00000
Company CEO: Blaise Coleman
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cellulite|Edema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| APHRODITE | P2 |
Completed |
Cellulite|Edema |
2023-01-03 |
2% |
2023-08-02 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/10/2025 |
News Article |
Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics |
|
10/15/2025 |
News Article |
Endo Announces Peyronie's Disease Presentation at the North Central Section of the American Urological Association |
|
10/09/2025 |
News Article |
Endo Announces Nine New and Modified Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting |
|
09/10/2025 |
News Article |
Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Orthopaedic Foot & Ankle Society Annual Meeting |